IDO1 and melanoma: A six-gene IFN-γ signature (including IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFNG) was identified in a melanoma cohort of the KEYNOTE-001 study to predict response to pembrolizumab (Ribas et al., 2015).